Expedited Programs for Regenerative Medicine Therapies for Serious Conditions: Draft Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
September 24, 2025
September 24, 2025
4c570099-1582-4019-8f81-d0260a2e984c
Related Documents
Potency Assessment of Active Immunotherapy Products
Guidance DocumentAugust 19, 2026Center for Biologics Evaluation and Research
Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing
Guidance DocumentApril 14, 2026Center for Biologics Evaluation and Research
Potency Assurance for Cellular and Gene Therapy Products
Guidance DocumentDecember 27, 2023Center for Biologics Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.